Fas Ligand Expression in Human and Mouse Cancer Cell Lines; a Caveat on Over-reliance on MRNA Data

Overview

Journal J Carcinog

Publisher Biomed Central

Date 2006 Feb 7

PMID 16457714

Citations 6

Authors

Aideen E Ryan

Sinead Lane

Fergus Shanahan

Joe OConnell

Aileen M Houston

Affiliations

Soon will be listed here.

Abstract

Background: During carcinogenesis, tumors develop multiple mechanisms for evading the immune response, including upregulation of Fas ligand (FasL/CD95L) expression. Expression of FasL may help to maintain tumor cells in a state of immune privilege by inducing apoptosis of anti-tumor immune effector cells. Recently this idea has been challenged by studies reporting that tumor cells of varying origin do not express FasL. In the present study, we aimed to comprehensively characterize FasL expression in tumors of both murine and human origin over a 72 hour time period.

Methods: RNA and protein was extracted from six human (SW620, HT29, SW480, KM12SM, HCT116, Jurkat) and three mouse (CMT93, CT26, B16F10) cancer cell lines at regular time intervals over a 72 hour time period. FasL expression was detected at the mRNA level by RT-PCR, using intron spanning primers, and at the protein level by Western Blotting and immunofluorescence, using a polyclonal FasL- specific antibody.

Results: Expression of FasL mRNA and protein was observed in all cell lines analysed. However, expression of FasL mRNA varied dramatically over time, with cells negative for FasL mRNA at many time points. In contrast, 8 of the 9 cell lines constitutively expressed FasL protein. Thus, cells can abundantly express FasL protein at times when FasL mRNA is absent.

Conclusion: These findings demonstrate the importance of complete analysis of FasL expression by tumor cells in order to fully characterize its biological function and may help to resolve the discrepancies present in the literature regarding FasL expression and tumor immune privilege.

Citing Articles

Destabilizing the genome as a therapeutic strategy to enhance response to immune checkpoint blockade: a systematic review of clinical trials evidence from solid and hematological tumors.

Alotaibi F, Alshammari K, Alotaibi B, Alsaab H Front Pharmacol. 2024; 14:1280591.

PMID: 38264532 PMC: 10803447. DOI: 10.3389/fphar.2023.1280591.

Spermatogonia apoptosis induction as a possible mechanism of induced male infertility.

Saki J, Sabaghan M, Arjmand R, Teimoori A, Rashno M, Saki G Iran J Basic Med Sci. 2020; 23(9):1164-1171.

PMID: 32963738 PMC: 7491504. DOI: 10.22038/ijbms.2020.43535.10224.

Expression of TRAIL-splice variants in gastric carcinomas: identification of TRAIL-γ as a prognostic marker.

Krieg A, Mersch S, Wolf N, Stoecklein N, Verde P, am Esch 2nd J BMC Cancer. 2013; 13:384.

PMID: 23937794 PMC: 3751299. DOI: 10.1186/1471-2407-13-384.

Potential for modulation of the fas apoptotic pathway by epidermal growth factor in sarcomas.

Joyner D, Jones K, Lessnick S, Schiffman J, Randall R Sarcoma. 2011; 2011:847409.

PMID: 22135505 PMC: 3206362. DOI: 10.1155/2011/847409.

Statins stimulate in vitro membrane FasL expression and lymphocyte apoptosis through RhoA/ROCK pathway in murine melanoma cells.

Sarrabayrouse G, Synaeve C, Leveque K, Favre G, Tilkin-Mariame A Neoplasia. 2007; 9(12):1078-90.

PMID: 18084615 PMC: 2134904. DOI: 10.1593/neo.07727.

References

Tourneur L, Malassagne B, Batteux F, Fabre M, Mistou S, Lallemand E . Transgenic expression of CD95 ligand on thyroid follicular cells confers immune privilege upon thyroid allografts. J Immunol. 2001; 167(3):1338-46. DOI: 10.4049/jimmunol.167.3.1338. View

Hohlbaum A, Gregory M, Ju S, Marshak-Rothstein A . Fas ligand engagement of resident peritoneal macrophages in vivo induces apoptosis and the production of neutrophil chemotactic factors. J Immunol. 2001; 167(11):6217-24. DOI: 10.4049/jimmunol.167.11.6217. View

Abrahams V, Straszewski S, Kamsteeg M, Hanczaruk B, Schwartz P, Rutherford T . Epithelial ovarian cancer cells secrete functional Fas ligand. Cancer Res. 2003; 63(17):5573-81. View

Gastman B, Atarshi Y, Reichert T, Saito T, Balkir L, Rabinowich H . Fas ligand is expressed on human squamous cell carcinomas of the head and neck, and it promotes apoptosis of T lymphocytes. Cancer Res. 1999; 59(20):5356-64. View

Pinkoski M, Green D . Fas ligand, death gene. Cell Death Differ. 2000; 6(12):1174-81. DOI: 10.1038/sj.cdd.4400611. View

Restifo N . Not so Fas: Re-evaluating the mechanisms of immune privilege and tumor escape. Nat Med. 2000; 6(5):493-5. PMC: 1955754. DOI: 10.1038/74955. View

Tinhofer I, Wykypiel H, Marschitz I, Henn T, Greil R . Gastric cancer cell lines lack Fas ligand (FasL) expression but kill T cells via a FasL independent pathway. Gut. 2000; 46(5):738-40. PMC: 1727931. DOI: 10.1136/gut.46.5.738. View

OConnell J, Houston A, Bennett M, OSullivan G, Shanahan F . Immune privilege or inflammation? Insights into the Fas ligand enigma. Nat Med. 2001; 7(3):271-4. DOI: 10.1038/85395. View

Brunner T, Wasem C, Torgler R, Cima I, Jakob S, Corazza N . Fas (CD95/Apo-1) ligand regulation in T cell homeostasis, cell-mediated cytotoxicity and immune pathology. Semin Immunol. 2003; 15(3):167-76. DOI: 10.1016/s1044-5323(03)00035-6. View

10.

Martinez-Lorenzo M, Anel A, Alava M, Pineiro A, Naval J, Lasierra P . The human melanoma cell line MelJuSo secretes bioactive FasL and APO2L/TRAIL on the surface of microvesicles. Possible contribution to tumor counterattack. Exp Cell Res. 2004; 295(2):315-29. DOI: 10.1016/j.yexcr.2003.12.024. View

11.

Ryan A, Shanahan F, OConnell J, Houston A . Addressing the "Fas counterattack" controversy: blocking fas ligand expression suppresses tumor immune evasion of colon cancer in vivo. Cancer Res. 2005; 65(21):9817-23. DOI: 10.1158/0008-5472.CAN-05-1462. View

12.

Griffith T, Brunner T, Fletcher S, Green D, Ferguson T . Fas ligand-induced apoptosis as a mechanism of immune privilege. Science. 1995; 270(5239):1189-92. DOI: 10.1126/science.270.5239.1189. View

13.

Nagata S, Golstein P . The Fas death factor. Science. 1995; 267(5203):1449-56. DOI: 10.1126/science.7533326. View

14.

Bellgrau D, Gold D, Selawry H, Moore J, Franzusoff A, Duke R . A role for CD95 ligand in preventing graft rejection. Nature. 1995; 377(6550):630-2. DOI: 10.1038/377630a0. View

15.

Hahne M, Rimoldi D, Schroter M, Romero P, Schreier M, French L . Melanoma cell expression of Fas(Apo-1/CD95) ligand: implications for tumor immune escape. Science. 1996; 274(5291):1363-6. DOI: 10.1126/science.274.5291.1363. View

16.

OConnell J, OSullivan G, Collins J, Shanahan F . The Fas counterattack: Fas-mediated T cell killing by colon cancer cells expressing Fas ligand. J Exp Med. 1996; 184(3):1075-82. PMC: 2192789. DOI: 10.1084/jem.184.3.1075. View

17.

Allison J, Georgiou H, Strasser A, Vaux D . Transgenic expression of CD95 ligand on islet beta cells induces a granulocytic infiltration but does not confer immune privilege upon islet allografts. Proc Natl Acad Sci U S A. 1997; 94(8):3943-7. PMC: 20547. DOI: 10.1073/pnas.94.8.3943. View

18.

Arai H, Chan S, Bishop D, Nabel G . Inhibition of the alloantibody response by CD95 ligand. Nat Med. 1997; 3(8):843-8. DOI: 10.1038/nm0897-843. View

19.

Arai H, Gordon D, Nabel E, Nabel G . Gene transfer of Fas ligand induces tumor regression in vivo. Proc Natl Acad Sci U S A. 1998; 94(25):13862-7. PMC: 28398. DOI: 10.1073/pnas.94.25.13862. View

20.

Berthou C, Michel L, Soulie A, Jean-Louis F, Flageul B, Dubertret L . Acquisition of granzyme B and Fas ligand proteins by human keratinocytes contributes to epidermal cell defense. J Immunol. 1998; 159(11):5293-300. View